Scarica l'app Stockscreener
53.25
0.02%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance UK
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - ulpravda.ru
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - ulpravda.ru
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Analyst Calls: How risky is Crinetics Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - ulpravda.ru
Crinetics Pharmaceuticals (CRNX): Analyst Updates on Price Targe - GuruFocus
Crinetics stock price target lowered to $105 by Citizens on endocrinologist survey - Investing.com UK
US Market Wrap: Will Crinetics Pharmaceuticals Inc 6Z4 stock issue positive guidance2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics’ Stocks Surge: Promising Future or Mirage? - timothysykes.com
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Shares Rise After Pricing $350 Million Stock Offering - MarketScreener
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Asianet Newsable
Crinetics Pharmaceuticals’ Stock Surges after Positive Trial Results and Analyst Boosts - timothysykes.com
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits - TechStock²
Crinetics (CRNX) Stock Soars Over 12% Amid Market Activity - GuruFocus
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
Crinetics Pharma climbs after $350 mln stock sale - TradingView — Track All Markets
Crinetics Pharmaceuticals (CRNX) Stock Analysis: A Deep Dive Into 71% Upside Potential - DirectorsTalk Interviews
Crinetics Prices $350 Million Stock Offering - MarketScreener
Crinetics Pharmaceuticals prices public offering at $45.95 per share - Investing.com India
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - The Manila Times
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Prices Public Offering of 7.62 Million Shares at $45.95 Each, Anticipating $350 Million in Proceeds - Quiver Quantitative
Crinetics Pharmaceuticals prices public offering of 7.6 million shares at $45.95 each - MarketScreener
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M - Intellectia AI
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Exact Sciences (EXAS) - The Globe and Mail
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00 - MarketBeat
Early PALSONIFY Launch and Atumelnant Data Might Change The Case For Investing In Crinetics (CRNX) - simplywall.st
Crinetics Pharmaceuticals shares down 6.4% after announcing $350 million stock offering - MarketScreener
Crinetics stock outperforms with strong Palsonify sales, Oppenheimer reiterates $87 target - Investing.com Nigeria
Crinetics stock maintains Buy rating at H.C. Wainwright on strong CAH data - Investing.com
Crinetics Pharma ticks down after announcing $350 mln stock offering - TradingView — Track All Markets
Crinetics Pharmaceuticals plans $350 million stock offering By Investing.com - Investing.com Nigeria
Crinetics reports over $5 million in Q4 revenue from acromegaly drug - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD - Investing.com
Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares - TipRanks
Crinetics Pharmaceuticals Stock: Biotech Optimism Meets Volatile Reality - AD HOC NEWS
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Crinetics stock soars after strong PALSONIFY launch and positive trial data - Investing.com
Crinetics plans $350 mln public share offering - MSN
Crinetics Reports Strong Palsonify Launch To Date, Positive Phase II CAH Data - Citeline News & Insights
Crinetics Pharmaceuticals announces proposed public offering of common stock - MarketScreener
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress - TipRanks
Crinetics Pharmaceuticals Plans $350 Million Public Offering - MarketScreener
Crinetics Pharmaceuticals plans $350 million stock offering - Investing.com India
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):